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Abstract
Little is known about the relationships between patient factors and the antihyperglycemic agents that have been prescribed as initial
therapy by diabetes specialists for patients with type 2 diabetes. Moreover, there has been little clariﬁcation of the subsequent usage
patterns and related factors that inﬂuenced the continuation or discontinuation of the drug or the addition of another drug. To provide
information on these issues, we evaluated the clinical characteristics of Japanese patients with type 2 diabetes for whom different
types of oral hypoglycemic agents (i.e., either sulfonylureas, biguanides, or DPP-4 inhibitors (DPP-4Is)) were chosen as initial
monotherapy by diabetes specialists and evaluated subsequent usage patterns.
Prescription data on 3 different antidiabetic agents from December 2009 to March 2015 from diabetes specialists’ patient
registries were used to identify variables at baseline related to initial prescriptions; also, the addition of another hypoglycemic drug or
discontinuation of the initial therapy was evaluated 1 year after the initial prescription. Analyzed were data on 2666 patients who
received initial monotherapy with either a sulfonylurea (305 patients), biguanide (951 patients), or DPP-4I (1410 patients). Patients
administered sulfonylureas were older, had a lower body mass index (BMI), longer duration of diabetes, and worse glycemic control
than recipients of biguanides. Use of biguanides was related to younger age, short duration of diabetes, and obesity but was
negatively associated with poor glycemic control. Older age but neither obesity nor poor glycemic control was associated with DPP-
4Is. In all 3 groups a high HbA1c value was related to adding another hypoglycemic agent to the initial therapy. Moreover, adding
another drug to a DPP-4I was related to a younger age and higher BMI.
Patients’ age, duration of diabetes, obesity, and glycemic control at baseline inﬂuenced the choice of hypoglycemic agents.
Selection of a biguanide differs greatly from that of a sulfonylurea or DPP-4I with regard to age and obesity.
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1. Introduction
Metformin was recommended as a ﬁrst-line treatment option for
type 2 diabetes mellitus (T2DM) in the consensus statement from
the American Diabetes Association (ADA) and the European
Association for the Study of Diabetes (EASD), but ∼40% of
patients received an initial oral antidiabetic drug other than
metformin in the United States and Italy.[1–3] These observations
suggest that physicians consider other factors (e.g., age, glycemic
control, duration of diabetes before the initial prescription of an
antidiabetic drug, obesity, complications, risk of hypoglycemia,
comorbidities, and life expectancy) when choosing an initial
antidiabetic drug.
The choice of medication should depend on individual patient
factors while strictly adhering to clinical guidelines.[4,5] Physi-
cians, especially diabetes specialists, can be expected to choose
hypoglycemic medications in consideration of factors that
inﬂuence the overall health and clinical outcome of each patient,
with particular concern regarding cardiovascular diseases.
However, little is known about the relationship between patient
factors identiﬁed at the time of the initial therapy (i.e., baseline
data) and the initial monotherapies prescribed by diabetes
specialists or about the continuation of an initially prescribed
hypoglycemic agent over a prolonged period, its possible
discontinuation, and the prescription of an additional agent.
Japan’s universal health coverage allows doctors to prescribe
hypoglycemic medications within a combination of 3 types of
hypoglycemic agents.[6] The choice of a hypoglycemic agent has
depended on individual physicians’ considerations of the
patient’s background in relation to diabetes since there are no
speciﬁc guidelines in Japan on the appropriate use of these
agents.[5] The ﬁrst drug of choice has dramatically changed in
Japan, since several new drugs, as represented by dipeptidyl
peptidase-4 inhibitors (DPP-4I), have been developed during the
last decade.[7–9] In fact, a recent study revealed that the top three
initially prescribed hypoglycemic agents in Japan were DPP-4I,
biguanides, and sulfonylureas in that order.[9]
The Japan Diabetes Clinical Data Management Study Group
(JDDM) is one of the largest cohorts of Japanese diabetes
specialists consisting of more than 120 leading clinical
diabetologists in 98 facilities and has provided information on
characteristics of patients with T2DM as well as hypoglycemic
prescriptions in Japan.[7,8,10,11] Therefore, using JDDM data we
sought to determine the factors that inﬂuence the choice of each
of 3 hypoglycemic agents prescribed as initial monotherapy by
specialists as well as the patients’ factors that inﬂuenced the
continuation or discontinuation of the drug or the addition of
another drug over a 1-year period. Such information would be
helpful in guiding the treatment of patients with T2DM by
diabetes specialists and physicians in general practice in clinical
settings.
2. Methods
Data were extracted by software (CoDiC) from the JDDM on
patients prescribed hypoglycemic agents from December 2009 to
March 2015. Details on the JDDM and CoDiC were described
elsewhere.[7,8,10,11] We included as participants individuals who
were aged 20 years or older who started medical treatment
(sulfonylureas, biguanides, or DPP-4Is) in outpatient clinics for
T2DM. Of the 3555 participants who received initial mono-
therapy during the above period, including a 1-year follow-up
after the ﬁrst prescription, we excluded 889 individuals because
of prescription of another antidiabetic medicine including insulin
as initial therapy or missing data. Thus, data on 2666 patients
who were prescribed sulfonylureas, biguanides, or DPP-4Is as the
initial medical treatment were analyzed. Of these, sulfonylureas,
biguanides, and DPP-4Is were administered to 305, 951, and
1410 patients, respectively. The present study was approved by
the ethics committee of the JDDM. Informed consent was
obtained from all patients at each participating institute in
accordance with the Guidelines for Epidemiological Studies of the
Ministry of Health, Labor and Welfare of Japan.
HbA1c was converted from the Japanese Diabetes Society
values into National Glycohemoglobin Standardization Program
equivalent values.[12] Hypertension was deﬁned as systolic blood
pressure ≥140mm Hg and/or diastolic blood pressure ≥90mm
Hg or the current use of antihypertensive agents.
2.1. Statistical analysis
Categorical variables were expressed as numerals and percen-
tages and were compared with x2 tests. Continuous variables
were expressed as mean±SD and were compared using the
Kruskal–Wallis test for comparisons in each group. Multinomial
logistic regression analysis and logistic regression analyses were
performed to identify variables related to each hypoglycemic
agent prescribed for initial monotherapy. Logistic regression
analyses were also performed to identify variables related to the
addition of another drug to each initial therapy or the
discontinuation of each initial hypoglycemic monotherapy based
on data obtained 1 year after the initial prescription. Covariates
simultaneously included continuous variables or categories: age
(<50, 50–64, and ≥65 years), sex, duration of diabetes at the
beginning of the ﬁrst treatment (<10 and ≥10 years), body mass
index (BMI) (<25.0 and ≥25.0kg/m2), hypertension, HbA1c
(<8.0 and ≥8.0% (64mmol/mol)), and clinics. All statistical
analyses were performed by SPSS (version 19.0, Chicago, IL), and
statistical signiﬁcance was considered for P<0.05.
3. Results
Table 1 shows participants’ baseline characteristics according to
each of the 3 hypoglycemic medications prescribed as initial
monotherapy. Except for the value of diastolic blood pressure,
there were signiﬁcant differences among the 3 groups. Partic-
ipants who were prescribed sulfonylureas were older, had a lower
BMI, a longer duration of diabetes, and worse glycemic control
than those who were prescribed biguanides. In comparison with
patients prescribed a sulfonylurea or DPP-4I, participants who
were administered biguanides were younger, had a higher BMI,
and a shorter duration of diabetes. Participants who were
prescribed DPP-4Is were older, had a lower BMI, and a longer
duration of diabetes in comparison with those prescribed
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biguanides. Age and BMI were similar in participants who were
prescribed a sulfonylurea or DPP-4I, whereas the duration of
diabetes and HbA1c values were higher in those prescribed a
sulfonylurea than a DPP-4I. Supplemental Tables 1 and 2, http://
links.lww.com/MD/B565 show the results of logistic regression
analyses of odds ratios for variables according to the hypoglyce-
mic medications selected as monotherapy. Prescribing sulfony-
lureas was associated with older age, long duration of diabetes,
and an elevated level of HbA1c, but was negatively associated
with obesity. Prescribing biguanides was related to younger age,
short duration of diabetes, and obesity but was negatively
associated with an elevated HbA1c. The use of DPP-4Is was
related to older age, but was negatively associated with obesity
and an elevated HbA1c. Signiﬁcant interactions were observed
for variables according to the agent prescribed. For sulfonylureas,
interactions between age and BMI and age and HbA1c were
observed while for biguanides an interaction between BMI and
HbA1c was observed. With DPP-4Is we found interactions
between the duration of diabetes and BMI and the duration of
diabetes andHbA1c. Table 2 shows the results of themultinomial
logistic regression analysis of odds ratios for biguanides andDPP-
4I according to variables using sulfonylureas as the reference.
Patients who received biguanides as initial therapy had lower
odds ratios for age, duration of diabetes, hypertension, and an
elevated HbA1c compared with those started on sulfonylureas,
whereas the odds ratio for BMI was higher. Patients who received
DPP-4Is as initial therapy had lower odds ratios for the duration
of diabetes and an elevated HbA1c compared with those started
on sulfonylureas. Figure 1 shows results of the evaluation of
patterns of use of antidiabetic agents 1 year after the initial
prescription of 3 different drugs. The continuous use of
sulfonylureas, biguanides, and DPP-4Is occurred in 164
(54%), 625 (66%), and 1042 (74%) participants, respectively,
while 17 (6%), 13 (7%), and 74 (5%) of the participants
discontinued sulfonylureas, biguanides, and DPP-4Is, respective-
ly. An additional drug was added to sulfonylureas, biguanides,
and DPP-4Is in 77 (25%), 192 (20%), and 231 (16%)
participants, respectively. Table 3 and Supplemental Table 3,
http://links.lww.com/MD/B565 show the results of logistic
regression analyses for odds ratios of explanatory valiables
related to the addition of another hypoglycemic medication to
each initial hypoglycemic medication, indicating an intensiﬁed
treatment strategy. In all 3 groups there was an association
between the addition of another hypoglycemic medication and
the baseline HbA1c values. Moreover, the addition of another
drug to a DPP-4I was related to younger age and a higher BMI.
Supplemental Tables 4 and 5, http://links.lww.com/MD/B565
show the results of logistic regression analyses of odds ratios for
explanatory variables related to stopping each of the initially
prescribed hypoglycemic medications. Stopping the initial
biguanides therapy was associated with the degree of elevation
of HbA1c values at baseline.
4. Discussion
As far as we know, this is the ﬁrst large-scale study to investigate
the relationships between patient factors and initial monotherapy
Table 2
Odds ratios for explanatory variables by multinomial logistic
regression analysis for selected diabetes drug therapies.
BG DPP-4I
N 951 P 1410 P
Age, y 0.95 (0.94–0.96) <0.01 0.99 (0.98–1.01) 0.26
Sex, male 1.32 (0.99–1.77) 0.06 1.30 (1.00–1.69) 0.048
Duration of diabetes 0.94 (0.92–0.96) <0.01 0.96 (0.95–0.97) <0.01
Body mass index, kg/m2 1.19 (1.14–1.24) <0.01 1.03 (0.99–1.07) 0.09
Hypertension 0.67 (0.50–0.90) <0.01 0.90 (0.69–1.18) 0.46
HbA1c, % 0.65 (0.57–0.73) <0.01 0.68 (0.61–0.76) <0.01
Reference category: sulfonylureas. Odds ratios were adjusted by clinics.
BG=biguanides, DPP-4I=DPP-4 inhibitor, hypertension=SBP≥140 and/or DBP ≥90 or treatment.
Figure 1. Results of evaluation of patterns of usage of 3 antidiabetic agents 1 year after initial prescription. (A) Sulfonylureas, (B) biguanides, and (C) DPP-4Is as
monotherapy. BG=biguanides, DPP-4Is=dipeptidyl peptidase-4 inhibitors, SU=sulfonylureas.
Table 1
Characteristics of study participants according prescription of
each of 3 hypoglycemic drugs.
Characteristic SU BG DPP-4I P
Number of patients, n 305 951 1410
Age, y 62±12 56±11 64±11 <0.001
Age <50 y, % 32 (10) 244 (26) 147 (10) <0.001
Age 50–64 y, % 108 (35) 487 (51) 540 (38)
Age ≥65 y, % 165 (54) 220 (23) 723 (51)
Male/female 178/127 641/310 890/520 0.009
Body mass index, kg/m2 24.8±4.6 27.3±4.5 24.7±3.7 <0.001
Duration of diabetes, y 10.1±10.2 5.4±5.8 7.7±7.6 <0.001
Hypertension, n (%) 166 (54) 442 (47) 727 (52) 0.018
Systolic blood pressure, mm Hg 130±18 128±14 130±16 <0.001
Diastolic blood pressure, mm Hg 74±12 76±11 75±11 0.232
HbA1c, % (NGSP) 7.8±1.4 7.0±1.0 7.4±1.0 <0.001
HbA1c, mmol/mol (IFCC) 62±15 59±11 58±11
BG=biguanides, DPP41=DPP4 inhibitor, IFCC= International Federation of Clinical Chemistry,
NGSP=National Glycohemoglobin Standardization Program, SU= sulfonylureas.
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by 1 of 3 speciﬁc hypoglycemic agents provided by diabetes
specialists for T2DM in Japan. The choice of each hypoglycemic
agent was inﬂuenced by patients’ age, duration of diabetes,
obesity, and glycemic control at baseline. Moreover, the choice of
biguanides differs greatly from the choice of a sulfonylurea or
DPP-4I with regard to age and obesity, which might reﬂect
specialists’ consideration of insulin resistance, insulin secretion,
or side effects. These ﬁndings might partially reﬂect the consensus
of specialists as to what agents would be most suitable as initial
therapy for patients with particular characteristics, which is not
speciﬁed in the current consensus recommendations but is
valuable in clinical settings. Intensifying therapy through the
addition of one or more agents to a DPP-4I was related to
younger age and a higher BMI at baseline. This information
would provide guidance for pharmacotherapy based on special-
ists’ prescriptions as individualized therapy for T2DM, which
was emphasized in ADA/EASD consensus recommendations.[4]
The role of the initial therapy over the long term could be
important in the treatment of diabetes when key elements such as
continuation of the initially prescribed drug, discontinuation of
that drug, or the addition of another drug are considered.
Although metformin was recommended as ﬁrst-line therapy in
the ADA/EASD consensus recommendations, ∼40% of patients
initiating oral hypoglycemic medications did not receive the
recommended initial therapy with metformin.[1–3] Moreover, it
has not been clariﬁed whether these recommendations were
applicable to Asians, including Japanese, whose T2DM tends to
be characterized more by impaired insulin secretion than by
increased insulin resistance compared with Caucasians.[13–15]
Our study is the ﬁrst to show differences in factors that inﬂuence
the choice of each of 3 hypoglycemic medications by Japanese
diabetes specialists in a real world setting. These ﬁndings reﬂect
their opinions on the suitability of speciﬁc agents for speciﬁc
patients.
We found that prescribing sulfonylureas was related to older
age, a long duration of diabetes, and poor glycemic control, but
not obesity. Impaired insulin secretion had a greater impact on
the background of T2DM compared to insulin resistance in a
Japanese population.[13–15] In fact, Asians typically have a lower
mean BMI but a higher prevalence of diabetes compared with
Caucasians at similar BMI levels.[16] Our ﬁndings might reﬂect
the consensus of diabetes specialists that sulfonylureas could be
used to increase insulin secretion in Japanese T2DM patients.
Patients who received sulfonylureas as initial therapy had a lower
BMI and a long duration of diabetes at baseline compared with
those started on biguanides, indicating that the need for
sulfonylureas was more closely associated with impaired insulin
secretion than in those prescribed biguanides as initial mono-
therapy who required another hypoglycemic agent to achieve
glycemic control. No clinical characteristics were revealed to be
related to discontinuation of sulfonylureas as initial therapy.
However, we could not analyze separately participants who
stopped taking sulfonylureas due to hypoglycemia or whose
glycemic control had improved. Therefore, these results should be
interpreted with caution.
Prescribing biguanides was associated with a younger age,
short duration of diabetes, and obesity, but not poor glycemic
control or the presence of hypertension. Although biguanides are
not deﬁned as ﬁrst-line hypoglycemic agents in Japan, these
results are consistent with a previous study[17] and also with the
consensus statement of the ADA/EASD.[4] It is generally
considered that chronic biguanide use is weight-neutral[18] and
does not increase the risk of hypoglycemia.[19] Biguanides can
cause lactic acidosis, and avoiding their use is advised in patients
at risk for this side effect, such as older patients and those with
advanced renal insufﬁciency.[20] Our study results might support
the opinion that Japanese diabetes specialists considered a wide
range of indications for biguanides. Unfortunately, we could
not obtain information on renal failure among participants;
therefore, future studies are needed to assess these issues.
Prescribing an additional hypoglycemic agent to biguanides was
related to a higher baseline HbA1c level and the rate of
prescribing an additional drug was lower in patients ≥50 years
old compared to those <50 years of age. Discontinuing
biguanides as initial therapy was related to a lower HbA1c
value, suggesting that an improvement in glycemic control by
diet and exercise therapy in the initial phase might have led to
discontinuing biguanides.
The DPP-4I is a key drug in Asians, who are more likely to have
impaired insulin secretion compared with Caucasians. The DPP-
4I prescription rate has dramatically increased in Japan in recent
years.[8,9] In our study, prescribing a DPP-4I was associated with
older age, but was negatively related to obesity. In a previous
study, we found no association between DPP-4I prescription and
older age since our sample size was insufﬁcient and we could not
analyze separately participants newly prescribed a hypoglycemic
agent or only participants whose prescriptions had been changed
during outpatient care.[7] A recent study from United States
showed that prescribing DPP-4Is was associated with older
age.[21] The mechanism of DPP-4Is is to increase incretin levels,
leading to increased insulin secretion.[22] Thus, clinicians expect
the choice of a DPP-4I to lead to improvement of impaired insulin
secretion as well as reduced glucagon levels. Moreover, DPP-4Is
cause little hypoglycemia or weight gain.[23] Our study results
could support the opinion that Japanese diabetes specialists
expect a low risk of side effects from the choice of a DPP-4I. The
reason for the higher rate of continuous use of a DPP-4I
compared sulfonylurea was the lower HbA1c level at baseline in
the DPP-4I group than in the sulfonylurea group. Adding another
drug to a DPP-4I was related to a higher HbA1c value, younger
age, and higher BMI at baseline. A recent meta-analysis indicated
that DPP-4Is exhibited better glucose-lowering efﬁcacy in studies
consisting of ≥50% Asians compared with studies having<50%
Asians,[24] which is consistent with our ﬁndings. No clinical
characteristic was shown for discontinuing initial therapy with a
DPP-4I, suggesting the possibility of good tolerance of a DPP-4I
as ﬁrst-line therapy for T2DM in Asians. However, further
studies are needed to evaluate the effectiveness and safety of DPP-
4Is as initial therapy over a long period of time, including
evaluation of cardiovascular outcome.
Table 3
Odds ratios for explanatory variables by logistic regression
analysis for the addition of another diabetes drug.
SU BG DPP-4I
n 77 192 231
Age, y 0.99 (0.96–1.01) 0.99 (0.97–1.00) 0.98 (0.96–0.99)
Sex, male 0.98 (0.54–1.78) 1.30 (0.89–1.90) 1.02 (0.75–1.37)
Duration of diabetes 1.00 (0.96–1.01) 0.98 (0.94–1.01) 0.98 (0.96–1.00)
Body mass index, kg/m2 1.00 (0.92–1.08) 1.00 (0.96–1.05) 1.05 (1.01–1.10)
Hypertension 0.90 (0.50–1.61) 0.96 (0.67–1.38) 1.04 (0.76–1.41)
HbA1c, % 1.27 (1.01–1.61) 1.65 (1.41–1.95) 1.69 (1.48–1.92)
BG=biguanides, DPP-4I=DPP-4 inhibitor, hypertension=SBP ≥140 and/or DBP ≥90 or treatment,
SU= sulfonylureas.
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Several limitationsmust be addressed regarding this study. First,
we could not obtain information on the presence or absence of
diabetes complications, dementia, renal failure, psychiatric factors,
social factors, and comorbidities because of the incomplete data in
the CoDiC database. Moreover, we could not separately analyze
random glucose and postprandial glucose. Therefore, further
studies are necessary to clarify the relationships between the
prescription of each hypoglycemic medication and characteristics
of patients that require consideration of those important factors.
Second, our study revealed the associations between baseline
patient factors and the initialmonotherapies and in principle could
not prove causality. Third, the rate of use of hypoglycemic agents
other than sulfonylureas, biguanides, or DPP-4I was too small to
assess a relationship between each available hypoglycemic agent
and clinical characteristics. Moreover, the prescription periods
were too short to assess a relationship between the prescription of
SGLT-2 inhibitors and characteristics of participants. Further
studies are needed to clarify these points with an adequate number
of patients. Fourth, the resultsmay be limited to an ethnic Japanese
population with T2DM.
In conclusion, as far as we know, this is the ﬁrst study to
investigate the relationships between patient factors and initial
prescriptions of 3 different hypoglycemic agents provided by
diabetes specialists for patients with T2DM in Japan. Our results
revealed sharp differences in characteristics among patients who
were prescribed 3 hypoglycemic medications by diabetes
specialists. The choice of each hypoglycemic agent was inﬂuenced
by 4 factors determined at baseline: patients’ age, duration of
diabetes, obesity, and glycemic control. The choice of a biguanide
differs greatly from the choice of a sulfonylurea and DPP-4I with
regard to age and obesity, which suggests that the consideration
of factors by diabetes specialists is related to insulin secretion,
insulin resistance, or side effects. Intensiﬁed therapy by the
addition of one or more agents to a DPP-4I was related to a
younger age and a higher BMI at baseline. This information
would provide guidance for pharmacotherapy based on special-
ists’ prescriptions for T2DM as individualized therapy.
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